National Cancer Institute (NCI) researchers have isolated T-cell receptors (TCRs) reactive to the highly prevalent p53-Y220C and p53-R273C mutants. These TCRs can be used for a variety of therapeutic, diagnostic and research applications. NCI seeks licensing and/or co-development research collaborations for TCRs that recognize p53-Y220C and p53- R273C mutations, and methods for identifying p53 mutation-reactive T cell receptors.
Scientists at The National Cancer Institute (NCI) and The National Institute of Neurological Disorders and Stroke (NINDS) have invented a method of imaging glucose metabolism in vivo using MRI chemical shift imaging (CSI) experiments that relies on a simple, but robust and efficient, post-processing procedure by the higher dimensional analog of singular value decomposition, tensor decomposition. This new technology is denoising software for MRIs that significantly improves the measurement of low-intensity signals without the need for dynamic nuclear polarization (DNP). The scientists seek research co-development partners and/or licensees for their invention.
The National Cancer Institute (NCI) seeks licensees for humanized mice that express the human isomer of mesothelin (MSLN) in the thyroid. NCI created Bl6/TPO mice for studies of mesothelin as a target for research, diagnostic, or therapeutics involving human cancers.
The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.
National Cancer Institute (NCI) researchers have developed a novel software tool for uniform recording of Mitotic Figure (MF) counts via conventional and/or digital microscopy. With this technology, diagnostic centers can standardize electronic recording, summation, and transcription of clinical data during surgical pathology examination. NCI seeks licensing partners to further develop this application for use in diagnosis and detection of malignant cancers.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.
The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.
Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.
Device is used to guide a stream of oxygen or carbon dioxide over a dish of cells during fluorescence microscopy. Invention includes the 3D printing software to create the device. The device makes it possible to easily provide a steady source of oxygen or carbon dioxide to cells while operating a fluorescent microscope to oxidize fluorophores for later visualization in electron microscopy. NCI seeks commercial partners to license this technology.
Researchers from NCI and Rudgers University developed methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell.
The National Cancer Institute seeks parties interested in collaborative research to co-develop diagnostic methods for detection of cancer using spatial genome organization.